Related posts

Oil climbs, stocks moderately move13 Recession-Proof Stocks for Portfolio SafetyFlat Wednesday
Investor Insights

This summary was created by AI, based on 12 opinions in the last 12 months.

Experts have varying opinions on Abbott Labs (ABT-N), with some recommending it as a buy due to its excellent quarter and positive growth potential in the healthcare sector. The company's diversified global healthcare operations, strong dividend history, and success in the medical devices and diagnostics fields have garnered positive feedback. However, there are concerns about its valuation, acquisition-focused approach, and fluctuations in share prices post-earnings reports. Overall, the general sentiment is mixed but leaning towards the positive side.

Consensus
Mixed
Valuation
Fair Value
BUY
Abbott Labs

Outlook is fabulous. Recent lawsuits turning out fine. Would buy at $100/share. 

biotechnology / pharmaceutical
HOLD
Abbott Labs

Diversified businesses in medical devices, testing technology, pharma, nutrition. Selling off as a result of $60M judgement against competitor's infant formula, worries of contagion. Long-term, it will work out. 

biotechnology / pharmaceutical
PAST TOP PICK
Abbott Labs
(A Top Pick Apr 20/23, Down 2%)

Flat over the year. Wonderful product portfolio. Structural driver is heart/cardiac business. Reported yesterday, topline growth 2%. This number is misleading, as cardiac organic growth was 14%, and organic growth outside of diagnostics was 10%. Performing well, growing quite well, reasonable multiple. He'd buy today.

biotechnology / pharmaceutical
BUY
Abbott Labs
To enter a new position

Yes, buy. Almost always they report and the reaction is negative at first, then it recovers. BTW, they had an excellent quarter.

biotechnology / pharmaceutical
BUY ON WEAKNESS
Abbott Labs

They report Wednesday. Usually, shares climb after the report, then someone finds fault with a single line item, then shares fall. Buy on the dip the next day.

biotechnology / pharmaceutical
BUY
Abbott Labs

Likes healthcare in general, a larger weight for him. Chart's performing pretty decently relative to the S&P 500. Could give nice returns going forward. 

biotechnology / pharmaceutical
BUY
Abbott Labs

It's fallen so far and pays a good dividend. 

biotechnology / pharmaceutical
BUY
Abbott Labs

Medical devices, generics sold to EMs, nutrition. Lots of money during pandemic, money redeployed into new products. Attractive entry point. Yield is 2%, dividend increased every year.

biotechnology / pharmaceutical
TOP PICK
Abbott Labs

It is a diversified global health care company with four operating divisions.  Sales dropped dramatically after benefiting during Covid but the basic business is doing well with all divisions growing organically. Weight loss patients are using their drugs to monitor glucose. It has had 51 years of dividend increases.             Buy 19  Hold 7  Sell 0

(Analysts’ price target is $116.88)
biotechnology / pharmaceutical
BUY
Abbott Labs

Has owned this many years. She likes healthcare because of aging demographics. They made a lot of cash during Covid and have used that cash for M&A and R&D. Pays a nice 2.5% dividend. Has an established track record of raising their dividend annually. Trades at a reasonable PE. Lags healthcare, but still likes ABT. 

biotechnology / pharmaceutical
BUY
Abbott Labs

They beat their quarter due to their medical devices business

biotechnology / pharmaceutical
TOP PICK
Abbott Labs

It is a diversified medical device company with a large diagnostic business. It has made several acquisitions giving it a very diversified platform and is executing well in the cardio-vascular and diabetes fields.     Buy 20  Hold 7  Sell 1

biotechnology / pharmaceutical
BUY
Abbott Labs

Great company with long history of being shareholder friendly.
Dividend paid for ~100 years.
Excellent management team.


biotechnology / pharmaceutical
TOP PICK
Abbott Labs

Defensive. Very strong growth platform. Diagnostic business is right-sizing now, but organic growth of other businesses is double digits. Valuation is a bit more expensive at 23x earnings, but free cashflow yield is about 4%. 

Instead of innovation, they tend to acquire and enhance, which has been a knock against them. Big wins in cardiac portfolio and FreeStyle Libre glucose monitoring. Businesses are right in the sweet spot. Yield is 1.83%.

(Analysts’ price target is $123.14)
biotechnology / pharmaceutical
BUY
Abbott Labs

Reported an amazing quarter today, but the headlines reported a ho-hum beat. Shares lagged but eventually finished $8 higher today.

biotechnology / pharmaceutical
Showing 1 to 15 of 186 entries

Abbott Labs(ABT-N) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 9

Neutral - Hold Signals / Votes : 1

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 10

Stockchase rating for Abbott Labs is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Abbott Labs(ABT-N) Frequently Asked Questions

What is Abbott Labs stock symbol?

Abbott Labs is a American stock, trading under the symbol ABT-N on the New York Stock Exchange (ABT). It is usually referred to as NYSE:ABT or ABT-N

Is Abbott Labs a buy or a sell?

In the last year, 10 stock analysts published opinions about ABT-N. 9 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Abbott Labs.

Is Abbott Labs a good investment or a top pick?

Abbott Labs was recommended as a Top Pick by on . Read the latest stock experts ratings for Abbott Labs.

Why is Abbott Labs stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Abbott Labs worth watching?

10 stock analysts on Stockchase covered Abbott Labs In the last year. It is a trending stock that is worth watching.

What is Abbott Labs stock price?

On 2024-05-24, Abbott Labs (ABT-N) stock closed at a price of $103.95.